


Contents lists available at [ScienceDirect](https://www.sciencedirect.com)

Blood Cells, Molecules and Diseases

journal homepage: www.elsevier.com/locate/bcmd

Letter to the Editor

Severe immune thrombocytopenia after COVID-19 vaccination: Report of four cases and review of the literature



To the editor,

From December 2020, four COVID-19 vaccines have been worldwide administered under emergency use; in last months' cases of vaccine-related ITP have been reported [1–6] raising concern about this possible complication and the management of patients with preexisting autoimmune cytopenias.

Herein we report four cases of ITP following COVID-19 vaccination (Table 1) and a brief literature review.

#1: A 27-year-old man presented with hematomas and epistaxis, 10 days after receiving the first dose of BNT162b2 mRNA vaccine (Comirnaty). Blood tests showed a low platelet count ($1 \times 10^9/L$), with normal WBC e Hb. Peripheral blood film did not show platelet clumping, schistocytes or blasts; no significant findings were observed in biochemical and coagulation tests. He was diagnosed with ITP and therapy with prednisone 1 mg/kg/d was started. Because of no response after 48 h and persistent hemorrhagic diathesis the patient received IVIG 1 g/kg/day for 2 consecutive days with rapid response. However, when we started steroid tapering, platelets soon decreased; therefore, we shifted to dexamethasone 40 mg/d for 4 days every 2 weeks: he underwent 3 cycles obtaining complete response.

#2: A 63-year-old man was admitted to hospital because of epistaxis and hematomas developed 14 days after receiving the first dose of ChAdOx1-S (Vaxzevria) vaccination. Medical history was positive for diabetes mellitus and arterial hypertension. Blood tests revealed severe thrombocytopenia ($2 \times 10^9/L$) with only mild leukocytosis and a normal Hb. Coagulation times, kidney and liver function tests were normal. Autoimmune diseases, viral infections or hematologic malignancies were excluded. In the hypothesis of ITP, steroid therapy with methylprednisolone 1 mg/kg/d was started with an immediate improvement of platelet count. After 3 weeks, steroid tapering was started and continued maintaining complete response. The second dose of vaccination mRNA-1273 Moderna vaccine (Spikevax) was performed after 9 weeks from the first one without any worsening of the platelet count.

#3: A 39-year-old woman with a history of ITP completely resolved with dexamethasone and IVIG in 2012 and 2019, six days after receiving the second dose of BNT162b2 mRNA vaccine (Comirnaty), presented to emergency room with ecchymosis; her platelet count was $1 \times 10^9/L$: she received methylprednisolone 1 mg/kg/d and IVIG 0,4 g/kg/d for 5 consecutive days obtaining a partial response (platelets $41 \times 10^9/L$). One week later she developed petechiae on her right arm and platelets were $3 \times 10^9/L$; IVIG 1 g/kg/d were again given for 2 consecutive days and TPO-mimetic eltrombopag 50 mg/d started with initial response; dosage needed to be increased to 75

mg/d the following week because of a new drop of platelets. Afterwards platelets collapsed again to $5 \times 10^9/L$: she therefore started romiplostim obtaining partial response. She is ongoing evaluation for splenectomy.

#4: A 24-year-old male with a history ITP successfully treated with IVIG, in 2018 was diagnosed with wAHA: a bone marrow and a lymph node biopsy excluded a lymphoproliferative syndrome. High doses steroids, IVIG and rituximab led to full recovery. In 2021, 21 days after the first dose of Moderna mRNA vaccine he presented with a platelet count of $2 \times 10^9/L$. The rest of the blood count and LDH were normal. He had petechiae in the oropharynx and bilateral upper extremities. A tb CT was negative for lymphoproliferative disorders. The patient received IVIG 0,4 g/kg/day for 5 days and methylprednisolone 1 mg/kg/day. Despite an initial response, 17 days after he presented with bruises and a platelet count of $5 \times 10^9/L$. He received platelet transfusion and IVIG 1 g/kg/day for 2 days. He continued steroid therapy with a fast improvement in platelet count. A bone marrow biopsy yielded no evidence of lymphoproliferative disorder. Five weeks platelet count is normal and the steroid tapering is still ongoing.

Paulsen et al. reported 4 patients with severe ITP after having received of ChAdOx1 nCoV-19 adenoviral vector vaccine: three of four patients had a past medical history of autoimmune disorders or pre-existing mild thrombocytopenia but a stable platelet count; time from vaccination was 2–11 days and all patients obtained complete response to treatment [1]. Also Pfizer-Biontech mRNA vaccine have been related to ITP: a platelet drop was described 3–18 days after administration of first or second dose and generally successfully treated with steroids with or without IVIG. Some had a previous diagnosis of ITP with stable platelet count at the moment of vaccine administration [2–4]. Moderna vaccine-related ITP cases have been described, in a case severe and refractory prompting therapy with dexamethasone, IVIG, platelet transfusions, rituximab and eltrombopag [4,5]. Reports of ITP following Johnson and Johnson COVID-19 vaccine are present in literature too [6]. An overall incidence of thrombocytopenia, including ITP, after vaccination with Pfizer-BioNTech COVID-19 Vaccine or Moderna COVID-19 Vaccine is described in the case-series reported to the Vaccine Adverse Event Reporting System published on June 2021. The reporting rate of thrombocytopenia was 0.80 per million doses for both vaccines, less than the annual incidence rate of 3.3 ITP cases per 100,000 adults [7].

Our report describes four more cases of severe ITP following COVID-19 vaccination with both mRNA and adenoviral vector vaccine. Two patients had a new onset of severe ITP while two had a history of ITP but stable platelet values. Of note, while the first two were well managed

<https://doi.org/10.1016/j.bcmd.2021.102615>

Received 30 September 2021; Accepted 1 October 2021

Available online 7 October 2021

1079-9796/© 2021 Elsevier Inc. All rights reserved.